Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2026)

Revolution Medicines has reported Cash from Financing Activities for 8 years, with the latest figure at $238.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 27216.25% year-over-year to $238.7 million; the trailing twelve-month figure through Mar 2026 stood at $859.4 million (down 10.43% YoY), and the FY2025 full-year result was $621.5 million, down 35.22% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $238.7 million, down from $365.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $873.8 million in Q4 2024, with the low at -$1.6 million in Q3 2025.
• Average Cash from Financing Activities over 5 years is $197.1 million, with a median of $64.6 million recorded in 2023.
• Year-over-year, Cash from Financing Activities jumped 106196.72% in 2023 and tumbled 102.06% in 2025.
• Tracing RVMD's Cash from Financing Activities over 5 years: stood at $51.4 million in 2022, then surged by 1534.16% to $839.4 million in 2023, then climbed by 4.1% to $873.8 million in 2024, then sank by 58.15% to $365.7 million in 2025, then slumped by 34.71% to $238.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $238.7 million (Q1 2026), $365.7 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.

Peer Comparison